← Leaderboards
Mark Vincent Carreon Dela Cerna
Georgia Southern University
$441,926
Attributed
$441,926
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $266.1K · FY2024–25$500K$375K$250K$125K$0
'24
'25
Funding mix
By agency
NIH$441,926 · 2
By mechanism
R16$351,213 · 1
S15$90,713 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Drug Discovery”
- Gene Garrard Olinger · University Of Texas Med Br Galveston$23,000,000
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$13,657,841
- Colin Osborne · University Of Texas Med Br Galveston$10,407,745
- Taleen Hanania · Psychogenics, Inc.$9,482,040
Research focus
Drug DiscoverySuccessPublic Health RelevanceBiomedical ResearchUniversitiesAffinityEarly-Career FacultyEpithelial To Mesenchymal TransitionDisseminated Malignant NeoplasmComplexAreaBiological ProcessAwardDrug DesignCancer PatientBindingCancer ModelCancer TherapyAccelerationCatalogsCytoskeletonCessation Of LifeBiological MarkersAnchorage-Independent Growth
Grant awards (3)
PRL3 inhibitors as migrastatics and the molecular determinants of PRL3 druggability$175,354
R16 · FY2025 · GM · contact PI
Increasing capacity and capability of shared biochemistry/biomedical science instrumentation through acquisition of modern, high-speed centrifuges$90,713
S15 · FY2025 · OD · contact PI
PRL3 inhibitors as migrastatics and the molecular determinants of PRL3 druggability$175,859
R16 · FY2024 · GM · contact PI